MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company General and Administrative Expenses 2011-2026 | BMY
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.27 B | 8.41 B | 7.77 B | 7.81 B | 7.69 B | 7.66 B | - | - | 162 M | 91 M | 160 M | 877 M | 165 M | 158 M | 4.2 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.41 B | 91 M | 4.03 B |
Quarterly General and Administrative Expenses Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.71 B | 1.58 B | 1.98 B | 1.93 B | 2.37 B | 2 B | 1.93 B | 1.76 B | - | 1.93 B | 1.79 B | 1.83 B | - | 1.79 B | 1.88 B | 1.67 B | - | 1.71 B | 1.63 B | 1.61 B | - | 1.06 B | 1.08 B | 1.01 B | - | 1.1 B | 1.13 B | 980 M | - | 1.16 B | 1.19 B | 1.08 B | - | 1.14 B | 1.24 B | 1.07 B | - | 1.18 B | 1.14 B | 1.03 B | - | 1.03 B | 951 M | 957 M | - | 980 M | 1.04 B | 994 M | - | 1.07 B | 1 B | 1 B | - | 1.02 B | 1.04 B | 928 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.37 B | 928 M | 1.36 B |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
54 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
63.3 M | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
531 M | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
26 M | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
4.4 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
266 M | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Black Diamond Therapeutics
BDTX
|
27.5 M | $ 2.4 | -3.04 % | $ 132 M | USA |
 |
Beam Therapeutics
BEAM
|
114 M | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
2.43 B | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
8.57 M | $ 1.38 | -0.01 % | $ 2.04 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
4.31 M | $ 2.91 | 2.83 % | $ 908 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Benitec Biopharma
BNTC
|
6.97 M | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 109.85 | -0.34 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
34.5 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptose Biosciences
APTO
|
11.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.6 | 1.9 % | $ 1.39 B | Britain |
 |
Athira Pharma
ATHA
|
26.1 M | - | - | $ 269 M | USA |